Found: 24
Select item for more details and to access through your institution.
Longitudinal audit of assessment and pharmaceutical intervention for cardiovascular risk in the Australasian Diabetes Data Network.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 2, p. 354, doi. 10.1111/dom.14584
- By:
- Publication type:
- Article
Challenges and opportunities in real‐world evidence on the renal effects of sodium‐glucose cotransporter‐2 inhibitors.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 2, p. 177, doi. 10.1111/dom.14599
- By:
- Publication type:
- Article
A model‐based simulation of glycaemic control and body weight when switching from semaglutide to 3.0‐ and 4.5‐mg doses of once‐weekly dulaglutide.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 2, p. 302, doi. 10.1111/dom.14582
- By:
- Publication type:
- Article
Efficacy of canagliflozin versus metformin in women with polycystic ovary syndrome: A randomized, open‐label, noninferiority trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 2, p. 312, doi. 10.1111/dom.14583
- By:
- Publication type:
- Article
Patterns of insulin therapy and insulin daily doses in children and adolescents with type 1 diabetes in Germany.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 2, p. 296, doi. 10.1111/dom.14581
- By:
- Publication type:
- Article
Cardiovascular risk profiles: A cross‐sectional study evaluating the generalizability of the glucagon‐like peptide‐1 receptor agonist cardiovascular outcome trials REWIND, LEADER and SUSTAIN‐6 to the real‐world type 2 diabetes population in the United Kingdom
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 2, p. 289, doi. 10.1111/dom.14580
- By:
- Publication type:
- Article
Cardiovascular and microvascular outcomes with iGlarLixi versus iDegLira: A real‐world, population‐based cohort study.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 2, p. 348, doi. 10.1111/dom.14579
- By:
- Publication type:
- Article
The importance of addressing multiple risk markers in type 2 diabetes: Results from the LEADER and SUSTAIN 6 trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 2, p. 281, doi. 10.1111/dom.14578
- By:
- Publication type:
- Article
Influenza vaccination and prognosis for COVID‐19 in hospitalized patients with diabetes: Results from the CORONADO study.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 2, p. 343, doi. 10.1111/dom.14577
- By:
- Publication type:
- Article
Vagal afferent cholecystokinin receptor activation is required for glucagon‐like peptide‐1–induced satiation.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 2, p. 268, doi. 10.1111/dom.14575
- By:
- Publication type:
- Article
Comparison of treatment with insulin degludec and glargine U100 in patients with type 1 diabetes prone to nocturnal severe hypoglycaemia: The HypoDeg randomized, controlled, open‐label, crossover trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 2, p. 257, doi. 10.1111/dom.14574
- By:
- Publication type:
- Article
Effects of dipeptidyl peptidase‐4 inhibitors and sulphonylureas on cognitive and physical function in nursing home residents.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 2, p. 247, doi. 10.1111/dom.14573
- By:
- Publication type:
- Article
A phase 1 multiple‐ascending dose study of tirzepatide in Japanese participants with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 2, p. 239, doi. 10.1111/dom.14572
- By:
- Publication type:
- Article
Efficacy and safety of oral semaglutide by baseline age in Japanese patients with type 2 diabetes: A subgroup analysis of the PIONEER 9 and 10 Japan trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 2, p. 321, doi. 10.1111/dom.14571
- By:
- Publication type:
- Article
Effects of sodium‐glucose cotransporter 2 inhibitors on serum uric acid in patients with type 2 diabetes mellitus: A systematic review and network meta‐analysis.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 2, p. 228, doi. 10.1111/dom.14570
- By:
- Publication type:
- Article
Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pump‐treated type 1 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 2, p. 212, doi. 10.1111/dom.14567
- By:
- Publication type:
- Article
Effects of short‐acting exenatide added three times daily to insulin therapy on bone metabolism in type 1 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 2, p. 221, doi. 10.1111/dom.14568
- By:
- Publication type:
- Article
Maintenance of glycaemic control with liraglutide versus oral antidiabetic drugs as add‐on therapies in patients with type 2 diabetes uncontrolled with metformin alone: A randomized clinical trial in primary care (LIRA‐PRIME).
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 2, p. 204, doi. 10.1111/dom.14566
- By:
- Publication type:
- Article
Effects of glucagon‐like peptide‐1 receptor agonists on histopathological and secondary biomarkers of non‐alcoholic steatohepatitis: A systematic review and meta‐analysis.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 2, p. 337, doi. 10.1111/dom.14565
- By:
- Publication type:
- Article
Impact of kidney function on the safety and efficacy of insulin degludec versus insulin glargine U300 in people with type 2 diabetes: A post hoc analysis of the CONCLUDE trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 2, p. 332, doi. 10.1111/dom.14564
- By:
- Publication type:
- Article
Ultra rapid lispro (URLi) shows accelerated pharmacokinetics and greater reduction in postprandial glucose versus Humalog® in patients with type 1 diabetes mellitus in a randomized, double‐blind meal test early‐phase study.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 2, p. 196, doi. 10.1111/dom.14563
- By:
- Publication type:
- Article
Ultra rapid lispro (URLi) shows faster pharmacokinetics and reduces postprandial glucose excursions versus Humalog® in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test early‐phase study.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 2, p. 187, doi. 10.1111/dom.14561
- By:
- Publication type:
- Article
Underestimation of hypoglycaemia using patients' diaries compared with downloaded glucometer data: an ITAS post hoc analysis.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 2, p. 327, doi. 10.1111/dom.14560
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 2, p. 175, doi. 10.1111/dom.14426
- Publication type:
- Article